Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Insulin-Like Growth Factor I, Resistance To 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × dalotuzumab × Clear all
NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
81 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡